Skip to main content

Levomefolate, Calcium Acetylcysteine and Mecobalamin Algal Prescribing Information

Package insert / product label
Generic name: levomefolate calcium, methylcobalamin, acetylcysteine and schizochytrium
Dosage form: tablets
Drug class: Vitamin and mineral combinations

Medically reviewed by Last updated on Jun 21, 2022.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Prescription Vitamin B9-Containing Dietary Supplement


DESCRIPTION: Levomefolate Calcium/Acetylcysteine/Mecobalamin/Algal Powder (6 mg-600 mg-2 mg-90.314 mg) is an orally administered prescription dietary supplement, and should be administered under the supervision of a licensed medical practitioner.

INGREDIENTS: This product contains the following dietary ingredients:

CAS #151533-22-1
L-Methylfolate Calcium* 6 mg
Methylcobalamin 2 mg
N-Acetyl-L-Cysteine 600 mg
Algae Powder (schizochytrium) 90.314 mg

Other Ingredients: Silicified Microcrystalline Cellulose NF, Polyvinyl Alcohol, Croscarmellose Sodium NF, Titanium Dioxide, Polyethylene Glycol 3350, Magnesium Stearate (NF, Vegetable Source), Talc, Beet Powder Red (color), Caramel FCC (color), Carnauba Wax.

CAUTION: Contains milk (caseinate) and soy. Does NOT contain lactose, yeast or gluten.

If you are pregnant or nursing a baby, please ask a health professional.

KEEP THIS OUT OF REACH OF CHILDREN. This product is not recommended for use in children under the age of twelve.

All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.


Levomefolate Calcium/Acetylcysteine/Mecobalamin/Algal Powder (6 mg-600 mg-2 mg-90.314 mg) is indicated for the distinct nutritional requirements of patients in need of advanced vitamin B9 supplementation-specifically suboptimal vitamin B9 or maintenance-level needs, as determined by a licensed medical practitioner.

DOSAGE AND ADMINISTRATION: Usual adult dose is one caplet daily or as prescribed by a licensed medical practitioner.

Store at controlled room temperature 15°-30°C (59°-86°F). [See USP]. Protect from light and moisture. Dispense in a tight, light-resistant container. Notice: Contact with moisture may produce surface discoloration or erosion.

Call your medical practitioner about side effects. You may report side effects by calling 813-283-1344.

VITAMIN B9 REGULATION: The Federal Register Notices from 1971 to 1973 established that increased vitamin B9 was proper therapy in megaloblastic anemias of tropical and nontropical sprue, nutritional origin, pregnancy, infancy and childhood. Vitamin 9 metabolism can be affected by malabsorption issues which differ widely among population groups. The March 5, 1996 Federal Register Notice (61 FR 8760) states that "The agency concluded that the scientific literature did not support the superiority of any one source of vitamin B9 over others, and that the data were insufficient to provide a basis for stating that a specific amount of vitamin B9 is more effective than another amount [emphasis added]." The actual amount and source of vitamin B9 require a licensed medical practitioner's supervision to achieve a satisfactory maintenance level, and may exceed the 0.8 mg UL. The Federal Register Notice of August 2, 1973 (38 FR 20750) specifically states that "dietary supplement preparations are available without a prescription (21 CFR 121.1134). Levels higher than dietary supplement amounts are available only with a prescription. Oral preparations supplying more than 0.8 mg of vitamin B9 per dosage unit would be restricted to prescription dispensing and that a dietary supplement furnishing 0.8 mg could be prescribed when a maintenance level of 0.8 mg per day was indicated. When clinical symptoms have subsided and the blood picture and/or CSF vitamin B9 levels have become normal, a maintenance level should be used. Patients should be kept under close supervision and adjustment of the maintenance level made if relapse appears imminent. In the presence of alcoholism, hemolytic anemia, anticonvulsant therapy, or chronic infection, the maintenance level may need to be increased [emphasis added]." However, once the level of active vitamin B9 exceeds 0.8 mg - as prescribed dosages, then the product is no longer a medical food but a dietary management / prescription (Rx)-vitamin B9 regardless of pregnancy/lactation status in spite of the fact that folic acid - including reduced forms, may be added to medical foods as defined in section 5(b)(3) of the Orphan Drug Act (21 USC 360ee(b)(3)), or to food (21 CFR 172.345). In the Letter Regarding Dietary Supplement Health Claim for Folic Acid, Vitamin B6, and Vitamin B12 and Vascular Disease (Docket No. 99P-3029) dated November 28, 2000, FDA wrote "... high intakes of vitamin B9 may partially and temporarily correct pernicious anemia while the neurological damage of vitamin B12 deficiency progresses. IOM/NAS (1998) set the UL for all adults of 1 mg per day because of devastating and irreversible neurological consequences of vitamin B12 deficiency, the data suggesting that pernicious anemia may develop at a younger age in some racial or ethnic groups, and the uncertainty about the extent of the occurrence of vitamin B12 deficiency in younger age groups (IOM/NAS, 1998) [emphasis added]." Summary: This product is a dietary management product that - due to advanced vitamin B9 levels, requires administration under the care of a licensed medical practitioner, and the most appropriate way to do that is to provide the product as prescription for pedigree reporting and safety monitoring. The ingredients, indication or claims of this product are not to be construed to be drug claims.


Federal Register Notice of April 9, 1971 (36 FR 6843).
The Federal Register Notice of August 2, 1973 (38 FR 20750).
The Federal Register Notice of October 17, 1980 (45 FR 69044).
Letter Regarding Dietary Supplement Health Claim for Folic Acid, Vitamin
B6, and Vitamin B12 and Vascular Disease (Docket No. 99P-3029). November 28, 2000.
The Federal Register Notice of March 5, 1996 (61 FR 8760).
Letter Regarding Dietary Supplement Health Claim for Folic Acid With Respect to Neural Tube Defects (Docket No. 91N-100H). October 10, 2000.
Code of Federal Regulations Title 21 Section 172.345.
Code of Federal Regulations Title 21 Section 101.9(j)(8).

VITAMIN B9 MECHANISM OF ACTION: Vitamin B9 is essential for the production of certain coenzymes in many metabolic systems such as purine and pyrimidine synthesis. It is also essential in the synthesis and maintenance of nucleoprotein in erythropoiesis. It also promotes white blood cell (WBC) and platelet production in vitamin B9-deficiency anemia. Vitamin B9 is associated with methylation and transformylation biochemistry.

INTERACTIONS: Talk to your healthcare practitioner and/or pharmacist before taking or using any prescription or over-the-counter medicines or herbal/health supplements alongside this product.

ADVERSE REACTIONS: Allergic reactions have been reported following the use of oral and parenteral vitamin B9. Mild transient diarrhea, polycythemia vera, itching, transitory exanthema and the feeling of swelling of the entire body has been associated with cobalamin. Nausea, vomiting, diarrhea, transient skin rash, flushing, epigastric pain, and constipation have been associated with acetylcysteine.

Call your medical practitioner about side effects.

CONTRAINDICATIONS: This product is contraindicated in patients with a known hypersensitivity to any of the components contained in this product.

WARNINGS: Caution is recommended in patients with a history of bipolar illness. Mood elevation is possible in this population.

Caution is also recommended in patients taking anticonvulsant medications as vitamin B9 may interfere with anticonvulsant medication, and may lower seizure threshold.

Patients undergoing cancer treatment should consult their licensed medical practitioner for advice.

PRECAUTIONS: Vitamin B9 alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Vitamin B9 in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission may occur while neurological manifestations progress.

PREGNANCY and NURSING MOTHERS: This product is not intended for use as a prenatal/postnatal multivitamin for lactating and non-lactating mothers. This product contains B vitamins plus NAC. Talk with your medical practitioner before using if pregnant or lactating.

HOW SUPPLIED: Levomefolate Calcium/Acetylcysteine/Mecobalamin/Algal Powder (6 mg-600 mg-2 mg-90.314 mg) is supplied as a coated, gray caplet debossed "V324", dispensed in bottles of 1000 caplets.

This product is a prescription-vitamin B9 with or without other dietary ingredients that - due to increased vitamin B9 levels (AUG 2 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of B12 deficiency (pernicious anemia). Based on our assessment of the risk of obscuring pernicious anemia, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) - or similar product code, as required by pedigree reporting requirements and supply-chain control as well as - in some cases, for insurance-reimbursement applications.

Manufactured for:
Virtus Pharmaceuticals, LLC
Tampa, FL 33619

REV 5/2014

PRINCIPAL DISPLAY PANEL - 90 Tablet Bottle Label


NDC 76439-329-11

Levomefolate Calcium*/
Algal Powder

Algal Powder
(6 mg-600 mg-2 mg-90.314 mg)

Prescription Vitamin B9-Containing
Dietary Supplement


1000 Caplets Made in the USA

Made in the USA

levomefolate calcium, methylcobalamin, acetylcysteine and schizochytrium tablet, coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:76439-329
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Inactive Ingredients
Ingredient Name Strength
Product Characteristics
Color GRAY Score no score
Shape CAPSULE Size 19mm
Flavor Imprint Code V324
# Item Code Package Description
1 NDC:76439-329-11 1000 TABLET, COATED in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 05/09/2014 02/15/2015
Labeler - Virtus Pharmaceuticals (969483143)
Virtus Pharmaceuticals

Frequently asked questions